Data gathered: December 25
AI Stock Analysis - Merck & Company (MRK)
Analysis generated November 29, 2024. Powered by Chat GPT.
Merck & Co., Inc. is a global healthcare company that delivers innovative health solutions through its prescription medicines, vaccines, biologic therapies, and animal health products. The company operates through two segments: Pharmaceutical and Animal Health. With a broad range of products targeting various medical conditions, Merck has positioned itself as a leader in the pharmaceutical industry.
Stock Alerts - Merck & Company (MRK)
 |
Merck & Company | December 24 Employee Rating is up by 2.4% over the last month. |
|
Merck & Company | December 10 Job postings are down by 28.2% in the last couple of days. |
|
Merck & Company | December 9 Jared Moskowitz (member of U.S. congress) is buying shares |
|
Merck & Company | December 3 Job postings are down by 36% in the last couple of days. |
Alternative Data for Merck & Company
About Merck & Company
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, diabetes, and women's health, as well as vaccine products. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products.
| Price | $99.45 |
| Target Price | Sign up |
| Volume | 3,530,000 |
| Market Cap | $251B |
| Year Range | $95.54 - $131.04 |
| Dividend Yield | 3.3% |
| PE Ratio | 20.79 |
| Analyst Rating | 67% buy |
| Earnings Date | February 4 '25 |
| Industry | Drug Manufacturers |
In the news
 |
Investing in Merck (NYSE:MRK) three years ago would have delivered you a 43% gainDecember 19 - Yahoo |
 |
Merck & Co., Inc. (MRK) is Attracting Investor Attention: Here is What You Should KnowDecember 19 - Yahoo |
 |
Is Merck & Co. (MRK) a Cheap NYSE Stock to Invest in Now?December 19 - Yahoo |
BMO Capital Downgrades Merck (MRK)December 19 - Fintel |
|
|
Why Is Merck & Co., Inc. (MRK) Among the Best Dividend Stocks to Invest In?December 18 - Yahoo |
 |
Strong Fundamentals And Weight Loss Entry Make Merck (MRK) A BuyDecember 17 - Yahoo |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '24 | 16.7B | 6.71B | 9.95B | 3.16B | 4.09B | 1.570 |
| Q2 '24 | 16.1B | 6.41B | 9.71B | 5.46B | 7.33B | 2.280 |
| Q1 '24 | 15.8B | 5.99B | 9.79B | 4.76B | 6.74B | 2.070 |
| Q4 '23 | 14.6B | 9.62B | 5.01B | -1.23B | 679M | 0.030 |
| Q3 '23 | 16B | 6.77B | 9.19B | 4.75B | 7.2B | 2.130 |
Insider Transactions View All
| Davis Robert M filed to sell 348,327 shares at $125.4. February 15 '24 |
| Litchfield Caroline filed to sell 50,908 shares at $125.5. February 15 '24 |
| Romanelli Joseph filed to sell 19,569 shares at $124.9. February 14 '24 |
| Davis Robert M filed to sell 348,327 shares at $126.4. February 15 '24 |
| Davis Robert M filed to sell 373,651 shares at $125.7. February 15 '24 |
Similar companies
| Company | Price | AI Score | |
|---|---|---|---|
 |
Johnson & JohnsonJNJ |
$145.85 0% | 48 |
 |
Eli Lilly and CompanyLLY |
$792.8 0% | 61 |
 |
PfizerPFE |
$26.69 0% | 36 |
 |
AstrazenecaAZN |
$66.3 0% | 54 |
 |
AbbVieABBV |
$180 0% | 59 |
Congress Trading View All
| Politician | Filing Date | Type | Size |
|---|---|---|---|
| Jared Moskowitz |
Dec 9, 24 | Buy | $1K - $15K |
| Michael McCaul |
Nov 14, 24 | Sell | $1K - $15K |
| Ro Khanna |
Nov 11, 24 | Buy | $1K - $15K |
Read more about Merck & Company (MRK) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, facebook engagement, facebook followers, instagram followers, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, youtube subscribers, news mentions, customer reviews, business outlook & linkedin employees.
What is the Market Cap of Merck & Company?
The Market Cap of Merck & Company is $251B.
What is Merck & Company's PE Ratio?
As of today, Merck & Company's PE (Price to Earnings) ratio is 20.79.
When does Merck & Company report earnings?
Merck & Company will report its next earnings on February 4 '25.
What is the current stock price of Merck & Company?
Currently, the price of one share of Merck & Company stock is $99.45.
How can I analyze the MRK stock price chart for investment decisions?
The MRK stock price chart above provides a comprehensive visual representation of Merck & Company's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Merck & Company shares. Our platform offers an up-to-date MRK stock price chart, along with technical data analysis and alternative data insights.
Does MRK offer dividends to its shareholders?
Yes, Merck & Company (MRK) offers dividends to its shareholders, with a dividend yield of 3.3%. This dividend yield represents Merck & Company's commitment to providing value to its shareholders through both potential capital appreciation and steady income. Investors considering Merck & Company in their portfolio should factor in this dividend policy alongside the company's growth prospects and market position.
What are some of the similar stocks of Merck & Company?
Some of the similar stocks of Merck & Company are Johnson & Johnson, Eli Lilly and Company, Pfizer, Astrazeneca, and AbbVie.
.